Moderna's COVID-19 Vaccine Update

Jacinda Ardern said that "We will have to be managing COVID-19 until there's a vaccine." A recent press release from Moderna gives us troubling insight into how the vaccine race is unfolding. Moderna — a Bill Gates’ venture that has yet to produce a successful product — is one of the leading contenders in the race for a COVID-19 vaccine.

The Moderna press release takes a positive tone, but a close reading of it tells us that three out of the 15 initial high-dose test subjects experienced severe adverse effects "preventing daily activity and requiring medical attention." And, only eight of the 15 developed antibodies.

Researchers have been trying for 30 years to produce vaccines for other COVID family viruses with no success. These test vaccines tended to produce "binding" antibodies rather than "neutralising" antibodies. These "binding" antibodies seemed to put the animal and human test subjects more at risk, with the result being sometimes fatal.

Given the long history of coronavirus vaccine research, these troubling initial results are unsurprising. It seems like a poor idea to skip animal trials and rush the development of such a vaccine. And, it seems like an even worse idea to consider mandating it to whole populations.

Read more about this in Robert F. Kennedy's post "Vaccine Trial Catastrophe: Moderna Vaccine has 20% ‘Serious’ Injury Rate in High Dose Group"